Lumosa Therapeutics Past Earnings Performance
Past criteria checks 0/6
Lumosa Therapeutics's earnings have been declining at an average annual rate of -9.5%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been declining at an average rate of 25.1% per year.
Key information
-9.5%
Earnings growth rate
-1.2%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | -25.1% |
Return on equity | -17.5% |
Net Margin | -418.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Lumosa Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 57 | -238 | 48 | 369 |
30 Sep 23 | 53 | -86 | 44 | 323 |
30 Jun 23 | 41 | -121 | 46 | 307 |
31 Mar 23 | 32 | -165 | 42 | 292 |
31 Dec 22 | 27 | -495 | 40 | 280 |
30 Sep 22 | 22 | -862 | 38 | 369 |
30 Jun 22 | 18 | -239 | 36 | 388 |
31 Mar 22 | 18 | -156 | 35 | 381 |
31 Dec 21 | 17 | 96 | 34 | 406 |
30 Sep 21 | 21 | 339 | 33 | 330 |
30 Jun 21 | 22 | -177 | 31 | 319 |
31 Mar 21 | 22 | -144 | 37 | 291 |
31 Dec 20 | 22 | -323 | 38 | 317 |
30 Sep 20 | 168 | -333 | 46 | 302 |
30 Jun 20 | 169 | -364 | 47 | 271 |
31 Mar 20 | 167 | -272 | 41 | 274 |
31 Dec 19 | 172 | -241 | 56 | 238 |
30 Sep 19 | 30 | -134 | 59 | 230 |
30 Jun 19 | 61 | -68 | 62 | 205 |
31 Mar 19 | 59 | -114 | 66 | 172 |
31 Dec 18 | 61 | -50 | 53 | 131 |
30 Sep 18 | 45 | -109 | 46 | 119 |
30 Jun 18 | 15 | -146 | 46 | 131 |
31 Mar 18 | 19 | -183 | 42 | 155 |
31 Dec 17 | 35 | -213 | 47 | 173 |
30 Sep 17 | 32 | -225 | 45 | 208 |
30 Jun 17 | 30 | -248 | 44 | 236 |
31 Mar 17 | 38 | -223 | 43 | 243 |
31 Dec 16 | 12 | -230 | 34 | 244 |
30 Sep 16 | 22 | -204 | 30 | 212 |
30 Jun 16 | 22 | -231 | 23 | 251 |
31 Mar 16 | 10 | -247 | 23 | 245 |
31 Dec 15 | 10 | -235 | 21 | 241 |
30 Sep 15 | 0 | -271 | 22 | 264 |
30 Jun 15 | 0 | -239 | 25 | 222 |
31 Mar 15 | 0 | -189 | 23 | 176 |
31 Dec 14 | 0 | -157 | 22 | 145 |
Quality Earnings: 6535 is currently unprofitable.
Growing Profit Margin: 6535 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6535 is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.
Accelerating Growth: Unable to compare 6535's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6535 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.7%).
Return on Equity
High ROE: 6535 has a negative Return on Equity (-17.52%), as it is currently unprofitable.